Improves clinical outcomes1,2,4,†

Reduces avoidable resource utilization4,5,†

Adds value through pharmacy benefit


reduction in number of hypoglycemic events for T1DM1,†

(<55 mg/dL; −0.38/24-h day; P<0.0001)


reduction in number of hypoglycemic events for T2DM2,†

(<55 mg/dL; −0.12/24-h day; P=0.0017)


average reduction in HbA1c4,†

(at 2-4 months; 95% CI, −0.70% to −0.39%)


reduction in number of diabetes-related hospital admissions5,†

[over 12 months (P<0.05)]


reduction in acute diabetes events among patients with T2DM6,†


Advantages of pharmacy benefit

  • Utilization management

  • Operational efficiencies

  • Cost savingsǂ,§

Diabetes patient holds and discusses FreeStyle Libre reader with doctor

Time in Range: a new standard of care7

  • Every 10% increase in Time in Range can lower HbA1c by 0.8%.7

  • Time in Range complements HbA1c with more actionable information than using HbA1c alone for a wide range of people with diabetes.7

  • FreeStyle Libre Portfolio users spent 43% more time in range P<0.001 (38.5 scans/day vs 3.5 scans/day)7,†,||

Diabetes patient holds and discusses FreeStyle Libre reader with doctor

Highlights of clinical guidelines for the use of CGM

Several clinical organizations including the ADA, AACE, and ACE have published guidelines for the use of CGM in the management of diabetes.9,10 Highlights from the published guidelines are included below.

View highlights from clinical guidelines

American Diabetes Association (ADA)

The ADA published diabetes treatment guidelines as part of the 2021 Standards of Medical Care in Diabetes, making the following clinical and access recommendations specific to CGM9:

  • CGMs, when used properly along with insulin, are useful in lowering/maintaining HbA1c and/or reducing hypoglycemia for people with diabetes

  • CGM users should have access through third-party payers

American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE)

A 2019 consensus statement10 by the AACE and ACE on a comprehensive type 2 diabetes mellitus management algorithm describes the role of CGM, making the following clinical recommendations:

  • Patients' and clinicians' understanding of glucose trends has been enhanced for people with T2D who use CGM

  • In helping patients better understand their glucose trends, CGM may also help with adherence

  • In providing real-time glucose data, CGM may support prevention of hypoglycemia
The role of CGM in reducing costs and complications

Billing Codes

NDC Codes

  • 57599-0002-00: FreeStyle Libre 14 day reader11

  • 57599-0001-01: FreeStyle Libre 14 day sensor11
  • 57599-0803-00: FreeStyle Libre 2 reader11
  • 57599-0800-00: FreeStyle Libre 2 sensor11


For therapeutic CGM, use the following billing codes:

  • K0553: Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service12,¶
  • K0554: Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system12,¶
  • Class II Durable Medical Equipment (including FreeStyle Libre 2 system) does not utilize a modifier12,¶
  • KF modifier applies to Class III Durable Medical Equipment (including FreeStyle Libre 14 day system)12,¶

Please contact us for more information.

* Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 system has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.
ǂ Cost savings results from removal of manual prior authorization (PA) process. Under pharmacy benefit, PA’s can either be eliminated or automated via smart PA.
§ Does not apply to Medicare and Medicaid.
|| 70-180 mg/dL.
¶ As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.
# For FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose. 
** For FreeStyle Libre 2 system: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

References: 1. Bolinder, Jan, Ramiro Antuna, Petronella Geelhoed-Duijvestijn, Jens Kröger, and Raimund Weitgasser. “Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.” The Lancet 388, no. 10057 (2016): 2254-2263. 2. Haak, Thomas, Hélène Hanaire, Ramzi Ajjan, Norbert Hermanns, Jean-Pierre Riveline, and Gerry Rayman. “Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial.” Diabetes Therapy 8, no. 1 (2017): 55-73. 3. Deshmukh, Harshal, Emma G. Wilmot, Robert Gregory, Dennis Barnes, Parth Narendran, Simon Saunders, Niall Furlong et al. “Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit.” Diabetes Care 43, no. 9 (2020): 2153-2160. 4. Evans, Mark, Zoë Welsh, Sara Ells, and Alexander Seibold. “The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies.” Diabetes Therapy 11, no. 1 (2020): 83-95. 5. Fokkert, Marion, Peter van Dijk, Mireille Edens, Eglantine Barents, Jeanine Mollema, Robbert Slingerland, Reinold Gans, and Henk Bilo. “Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).” BMJ Open Diabetes Research and Care 7, no. 1 (2019). 6. Bergenstal, Richard M., Matthew SD Kerr, Gregory J. Roberts, Diana Souto, Yelena Nabutovsky, and Irl B. Hirsch. “69-OR: Freestyle Libre System Use Is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes.” (2020). Diabetes 69, no. Supplement 1 (2020). 7. Battelino, Tadej, Thomas Danne, Richard M. Bergenstal, Stephanie A. Amiel, Roy Beck, Torben Biester, Emanuele Bosi et al. “Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range.” Diabetes Care 42, no. 8 (2019): 1593-1603. 8. Lang, Jordan, Sujit Jangam, Timothy Dunn, and Gary Hayter. "972-P: Expanded real-world use reaffirms strong correlation between scanning frequency of flash glucose monitoring and glucose control." Diabetes 68, no. 1 (June 2019). DOI: 9. American Diabetes Association. “7. Diabetes technology: Standards of Medical Care in Diabetes --2021.” Diabetes Care 44, no. Supplement 1 (2021):S85 -S99. 10. Garber, Alan J., Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack et al. “Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm -2019 executive summary.” Endocrine Practice 25, no. 1 (2019): 69-100. 11. First DataBank, April 2020. 12. Centers for Medicare & Medicaid Services. Medicare Claims Processing. CMS publication 100-04. Published June 28, 2019. Accessed November 20, 2020.

ADC-17130 v3.0 01/21